BOULDER, Colo. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, and Archemix Corp., a biotechnology company focused on developing aptamer therapeutics, announced today that the two companies will collaborate on conjugated aptamer-microRNA therapies capable of intracellular delivery and subsequent microRNA targeting. miRagen and Archemix will jointly pursue research and development efforts and both companies will contribute resources under the agreement, which includes an exclusive option for miRagen to negotiate for exclusive rights to further develop and commercialize certain aptamer-microRNA therapeutics generated during the collaboration. Additional terms of the agreement were not disclosed.
